AU748754B2 - Treatment of hepatic cirrhosis - Google Patents

Treatment of hepatic cirrhosis Download PDF

Info

Publication number
AU748754B2
AU748754B2 AU76922/98A AU7692298A AU748754B2 AU 748754 B2 AU748754 B2 AU 748754B2 AU 76922/98 A AU76922/98 A AU 76922/98A AU 7692298 A AU7692298 A AU 7692298A AU 748754 B2 AU748754 B2 AU 748754B2
Authority
AU
Australia
Prior art keywords
group
halofuginone
compound
hepatic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76922/98A
Other languages
English (en)
Other versions
AU7692298A (en
Inventor
Arnon Nagler
Mark Pines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25338371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU748754(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hadasit Medical Research Services and Development Co, Agricultural Research Organization of Israel Ministry of Agriculture filed Critical Hadasit Medical Research Services and Development Co
Publication of AU7692298A publication Critical patent/AU7692298A/en
Application granted granted Critical
Publication of AU748754B2 publication Critical patent/AU748754B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU76922/98A 1997-05-23 1998-05-22 Treatment of hepatic cirrhosis Ceased AU748754B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86238297A 1997-05-23 1997-05-23
US08/862382 1997-05-23
PCT/US1998/010505 WO1998052514A2 (fr) 1997-05-23 1998-05-22 Traitement de la cirrhose hepatique

Publications (2)

Publication Number Publication Date
AU7692298A AU7692298A (en) 1998-12-11
AU748754B2 true AU748754B2 (en) 2002-06-13

Family

ID=25338371

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76922/98A Ceased AU748754B2 (en) 1997-05-23 1998-05-22 Treatment of hepatic cirrhosis

Country Status (8)

Country Link
EP (1) EP1014988A2 (fr)
JP (1) JP2002515905A (fr)
KR (1) KR100540537B1 (fr)
CN (1) CN1160073C (fr)
AU (1) AU748754B2 (fr)
CA (1) CA2290502C (fr)
IL (1) IL132848A (fr)
WO (1) WO1998052514A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039308A2 (fr) * 2002-10-31 2004-05-13 State Of Israel, Ministry Of Agriculture Compositions de quinazolinone destinees a reguler l'expression genetique dans des processus pathologiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
US5449678A (en) * 1994-01-11 1995-09-12 Agricultural Research Organization, Ministry Of Agriculture Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
US5449678A (en) * 1994-01-11 1995-09-12 Agricultural Research Organization, Ministry Of Agriculture Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof

Also Published As

Publication number Publication date
KR100540537B1 (ko) 2006-01-10
CN1160073C (zh) 2004-08-04
KR20010012838A (ko) 2001-02-26
CA2290502A1 (fr) 1998-11-26
CA2290502C (fr) 2007-08-28
EP1014988A2 (fr) 2000-07-05
AU7692298A (en) 1998-12-11
IL132848A0 (en) 2001-03-19
WO1998052514A3 (fr) 1999-08-19
IL132848A (en) 2004-08-31
CN1265034A (zh) 2000-08-30
WO1998052514A2 (fr) 1998-11-26
JP2002515905A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
US5672622A (en) Treatment of multiple sclerosis
JPH08510251A (ja) 線維症の病変の修復と予防のための組成物および方法
WO2000064470A1 (fr) Formulation pharmaceutique comportant un inhibiteur de thrombine de faible poids moleculaire et son promedicament
SK288707B6 (sk) Farmaceutické kombinácie obsahujúce antagonistu P2T receptora a ďalšie antitrombotické činidlá, spôsob ich prípravy a ich použitie na liečenie a prevenciu trombózy
US6562829B1 (en) Treatment of hepatic cirrhosis
CA2568436A1 (fr) Therapie combinee impliquant un antagoniste de recepteur d'adenosine a1 et un inhibiteur d'aldosterone
JP2002509540A (ja) アルドースレダクターゼ阻害剤およびａｃｅ阻害剤を含有する医薬組成物
AU2002309211B2 (en) Treatment of renal fibrosis
AU748754B2 (en) Treatment of hepatic cirrhosis
US5872124A (en) Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
JP2003503457A (ja) 心臓血管合併症の治療用薬剤の製造におけるアンギオテンシンｉｉ１型受容体アンタゴニストの使用
US7439077B2 (en) Coumarin analog compounds for safer anticoagulant treatment
AU2002309211A1 (en) Treatment of renal fibrosis
CA2285350A1 (fr) Traitement de la fibrose pulmonaire
AU2008315685A1 (en) Prevention of recurrence of urethral stricture after a conventional treatment
WO2001062241A1 (fr) Procede permettant de prevenir ou reduire les dysfonctionnements de l'acces vasculaire
WO1998001100A2 (fr) Methode de traitement de l'hypercholesterolemie familiale homozygote
AU2008201290B2 (en) Therapeutic treatment
US7041706B2 (en) Method for treating crohn's disease
CA2070149A1 (fr) Inhibiteurs de la reductase hmg-coa utilises pour la prevention de la restenose suivant une angioplastie coronarienne
AU2001250174B2 (en) Compositions and therapies for hyperlipidaemia-associated disorders
Whayne Women and cardiovascular disease—Prevention of heart disease
JP4504465B2 (ja) 肝線維化防止剤
WO2001097798A1 (fr) Procede servant a prevenir ou a reduire des evenements cardio-vasculaires induits par intervention coronarienne
Jack Latest drug research in rheumatology

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PROVIDE SEARCH RESULTS UNDER S45(3) HAS BEEN EXTENDED TO 20040401